In this report, we cover catalysts from 21 drugs expected to occur in Q3 2017. For each drug, the likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group are provided. At the end of this report, we have included a list of Large Impact catalysts through Q3 2017.
Our reports have been used by over 10K customers, including:
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.